Skip to main content

Errata - English

PDF CSV September 15, 2023 through September 15, 2025 All Errata for USP–NF How to use
Enter the title of the monograph
Monograph Title Section Source Publication Page Number Errata Official Date Target Errata Print Publication Target Online Fix Publication Description
CLARITHROMYCIN FOR ORAL SUSPENSION ASSAY/Procedure USP36–NF31 3018 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Change the subsection head
Buffer:
to:
Buffer A:
AND
After the Buffer A subsection: Add
Buffer B: 0.067 M dibasic potassium phosphate
AND
Line 1 of Mobile phase: Change
Methanol and Buffer
to:
Methanol and Buffer ARead More
CLARITHROMYCIN EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 4 USP36–NF31 3019 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of Standard solution: Change
and Medium (96:4).
to:
and Medium (4:96).
DACARBAZINE FOR INJECTION USP Reference standards <11> USP36–NF31 3137 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 3 of USP Dacarbazine Related Compound B RS: Change
C4H3N5O 137.10
to:
C4H3N5O · H2O 155.12
CRYOPRESERVED HUMAN FIBROBLAST-DERIVED DERMAL SUBSTITUTE Total collagen content USP36–NF31 3155 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 7 of Collagen calibration standards: Change
by adding 25 mL, 50 mL, 100 mL, and 200 mL,
to:
by adding 25 μL, 50 μL, 100 μL, and 200 μL,
DIPHENHYDRAMINE HYDROCHLORIDE CAPSULES Assay USP36–NF31 3276 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2: Change
Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride.
to:
Mobile phase—Prepare a solution of acetonitrile, water,… Read More
DIPHENHYDRAMINE HYDROCHLORIDE INJECTION Assay USP36–NF31 3276 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2: Change
Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride.
to:
Mobile phase—Prepare a solution of acetonitrile, water,… Read More
DIPHENHYDRAMINE HYDROCHLORIDE ORAL SOLUTION Assay USP36–NF31 3277 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2: Change
Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride.
to:
Mobile phase—Prepare a solution of acetonitrile, water,… Read More
EDETATE DISODIUM ASSAY/Procedure USP36–NF31 3370 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 5: Delete
Titrimetric system
(See Titrimetry <541>.)
Mode: Direct titration
Titrant: 0.1 N sodium hydroxide VS
Endpoint detection: Visual
EDETATE DISODIUM ASSAY/Procedure USP36–NF31 3370 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 16 of Analysis: Change
Calculate the percentage of edetate disodium
to:
Calculate the weight of edetate disodium
AND
Line 19 of Analysis: Change
Result = (VT/VU) × W × (Mr1/Mr2) ×… Read More
FELBAMATE TABLETS IMPURITIES/Organic Impurities/System suitability/Suitability requirements USP36–NF31 3537 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Resolution: Change
NMT 2
to:
NLT 2
FEXOFENADINE HYDROCHLORIDE TABLETS ASSAY/Procedure USP36–NF31 3576 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 6 of Sample stock solution: Change
(equivalent to 80% of the total flask volume)
to:
(sufficient to fill the flask to 80% of its volume)
FLUPHENAZINE DECANOATE INJECTION Assay USP36–NF31 3639 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 11 of Standard preparation: Delete
(1:5)
AND
Line 8 of Assay preparation: Delete
(1:5)
LAMOTRIGINE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 1 USP36–NF31 4056 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 3 of Standard solution: Change
0.028 µg/mL
to:
0.028 mg/mL
LEVOFLOXACIN ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP36–NF31 4099 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of USP Levofloxacin Related Compound A RS: Change
(S)-9-Fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4-benzoxazine-6-carbocylic acid.
to:
(S)-9-Fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-… Read More
MOXIFLOXACIN OPHTHALMIC SOLUTION Related compounds USP36–NF31 4414 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Row 1 of Column 3 of Table 2: Change
Relative Retention Time vs. Moxifloxacin
to:
Relative Retention vs. Moxifloxacin
AND
Row 1 of Column 3 of Table 3: Change
Relative Retention Time vs. Moxifloxacin
to:
Relative Retention vs. Moxifloxacin
NIFEDIPINE EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 4/Instrumental conditions USP36–NF31 4509 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Cell: Change
0.5 cm
to:
1 cm
OLMESARTAN MEDOXOMIL IMPURITIES/Organic Impurities/Impurity Table USP36–NF31 4570 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Footnote d: Change
((5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2´-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate.
to:
(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2´-(2-trityl-1… Read More
TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE TABLETS IMPURITIES/Organic Impurities/Table 2 USP36–NF31 5438 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Footnote c: Change
1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-1-ene hydrochloride (identified and reported as an individual unspecified impurity if present).
to:
1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-6-ene hydrochloride (identified and reported as an individual… Read More
VENLAFAXINE HYDROCHLORIDE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP36–NF31 5551 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of Venlafaxine Related Compound A RS: Change
1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol.
C16H25NO2
263.38
to:
1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride.
C16H25NO2… Read More
VENLAFAXINE TABLETS ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP36–NF31 5554 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of Venlafaxine Related Compound A RS: Change
1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol.
C16H25NO2
263.38
to:
1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride.
C16H25NO2… Read More
GYMNEMA IDENTIFICATION/B. Thin-Layer Chromatography/Chromatographic system First Supplement to USP36–NF31 5880 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of Adsorbent: Change
5m
to:
5 µm
POWDERED GYMNEMA IDENTIFICATION/B. Thin-Layer Chromatography/Chromatographic system First Supplement to USP36–NF31 5883 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of Adsorbent: Change
5m
to:
5 µm
PURIFIED GYMNEMA EXTRACT COMPOSITION/Content of Gymnemic Acids First Supplement to USP36–NF31 5884 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Acceptance criteria: Change
90%–110% of the labeled amount
to:
90.0%–110.0% of the labeled amount on the dried basis
GENTAMICIN SULFATE IMPURITIES/Limit of Methanol First Supplement to USP36–NF31 5990 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 11 of Analysis: Change
Result = (RU/RS) × (CS/CU) × D × F × 100
to:
Result = (RU/RS) × (CS Read More
MEPROBAMATE TABLETS ASSAY/Procedure First Supplement to USP36–NF31 6015 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 4 of Standard solution: Change
Dissolve in 30% of the final flask volume, and dilute with water to volume.
to:
Dissolve in 30% of the final flask volume of acetonitrile, and dilute with water to volume.
OXCARBAZEPINE IMPURITIES/Organic Impurities, Procedure 1 First Supplement to USP36–NF31 6035 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Row 4 of Column 1 of Table 1: Change
Dibenzazepinoneb
to:
Oxcarbazepine related compound E
AND
Delete footnote b
AND
Reletter the following footnotes in both the table and footnote definitions:
c to b
d to c
e to d
OXCARBAZEPINE IMPURITIES/Organic Impurities, Procedure 2 First Supplement to USP36–NF31 6035 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Row 9 of Column 1 of Table 3: Change
Oxcarbazepine related compound Eg
to:
Oxcarbazepine related compound E
AND
Delete footnote g
ISOTRETINOIN CAPSULES PERFORMANCE TESTS/Dissolution <711>/Test 4 Revision Bulletin (Official October 01, 2012) Online 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2 of Medium: Change
4.5% (v/v) of Milloxid L (lauryl dimethyl amine oxide)
to:
4.5% (v/v) of lauryl dimethyl amine oxide
<228> ETHYLENE OXIDE AND DIOXANE Method II USP36–NF31 148 1-Jun-2013 USP37–NF32 USP37–NF32 Line 31 of Analysis: Change
rS = ethylene oxide peak responses from Standard solution B
to:
rS = dioxane peak responses from Standard solution B
<1052> BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS METHODOLOGIES OF AMINO ACID ANALYSIS GENERAL PRINCIPLES USP36–NF31 619 1-Jun-2013 USP37–NF32 USP37–NF32 Change the section title
Method 6—Postcolumn DABS-CI Derivatization General Principle
to:
Method 6—Precolumn DABS-CI Derivatization General Principle
<1052> BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS APPENDIX USP36–NF31 619 1-Jun-2013 USP37–NF32 USP37–NF32 Change the section title
Method 6—Postcolumn DABS-CI Derivatization
to:
Method 6—Precolumn DABS-CI Derivatization
CARAWAY OIL DEFINITION USP36–NF31 1924 1-Jun-2013 USP37–NF32 USP37–NF32 Line 3: Change
It contains NMT 50.0% of d-carvone (C10H14O).
to:
It contains NLT 50.0% of d-carvone (C10H14O).
NITRIC ACID ASSAY/Procedure USP36–NF31 2107 1-Jun-2013 USP37–NF32 USP37–NF32 Line 1 of Sample solution: Change
To 2 mL of Nitric Acid in a tared, glass-stoppered conical flask add 25 mL of water.
to:
Weigh 2 mL of Nitric Acid in a glass-stoppered conical flask, and add 25 mL of water.
ALBUTEROL SULFATE Chromatographic purity USP36–NF31 2352 1-Jun-2013 USP37–NF32 USP37–NF32 Line 1: Change
It meets the requirements of the test for Chromatographic purity under Albuterol, except to read Albuterol Sulfate in place of Albuterol and to use water instead of methanol as the solvent to prepare the Standard solution and the Test solution.
to… Read More
AMITRIPTYLINE HYDROCHLORIDE TABLETS IDENTIFICATION/A. USP36–NF31 2464 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Sample solution: Nominally 0.01 mg/mL of amitriptyline hydrochloride in methanol from a suitable amount of finely powdered Tablets. Filter a portion of the solution, and use the filtrate for analysis.
to:
Sample stock solution: Nominally 0.1 mg/mL of… Read More
FOSPHENYTOIN SODIUM USP Reference standards <11> USP36–NF31 3679 1-Jun-2013 USP37–NF32 USP37–NF32 Line 6: Change
C14H15NO2
to:
C14H13NO2
FOSPHENYTOIN SODIUM INJECTION USP Reference standards <11> USP36–NF31 3680 1-Jun-2013 USP37–NF32 USP37–NF32 Line 6: Change
C14H15NO2
to:
C14H13NO2
FOSPHENYTOIN SODIUM INJECTION Assay USP36–NF31 3680 1-Jun-2013 USP37–NF32 USP37–NF32 Line 1 of Assay preparation: Change
Transfer an accurately measured volume of the Injection, equivalent to about 300 mg of fosphenytoin,
to:
Transfer an accurately measured volume of the Injection, equivalent to about 300 mg of fosphenytoin sodium,
MINOCYCLINE HYDROCHLORIDE CAPSULES Assay USP36–NF31 4375 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride.
to:
Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate… Read More
MINOCYCLINE FOR INJECTION Assay USP36–NF31 4375 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride.
to:
Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate… Read More
MINOCYCLINE HYDROCHLORIDE ORAL SUSPENSION Assay USP36–NF31 4376 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Mobile phase and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride.
to:
Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran (600:180… Read More
MINOCYCLINE HYDROCHLORIDE TABLETS Assay USP36–NF31 4378 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride.
to:
Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M… Read More
MOXIFLOXACIN OPHTHALMIC SOLUTION Assay USP36–NF31 4414 1-Jun-2013 USP37–NF32 USP37–NF32 Line 4 of Resolution solution: Change
0.1 mg per mg and 0.001 mg per mg,
to:
0.1 mg per mL and 0.001 mg per mL,
NIFEDIPINE EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 2 USP36–NF31 4509 1-Jun-2013 USP37–NF32 USP37–NF32 Line 1 of Solution A: Change
Dissolve 330.9 mg of sodium phosphate
to:
Dissolve 330.9 g of dibasic sodium phosphate
OXYCODONE AND ACETAMINOPHEN TABLETS IDENTIFICATION/A. Thin-Layer Chromatography USP36–NF31 4645 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2 of Sample solution: Change
in a mixture of methanol and water (4:1).
to:
in a 5-mL mixture of methanol and water (4:1).
OXYCODONE TEREPHTHALATE ASSAY/Procedure USP36–NF31 4648 1-Jun-2013 USP37–NF32 USP37–NF32 Line 7 of Analysis: Change
RU = internal standard ratio (peak response of oxycodone/peak response of ethylparaben) from the Standard solution
RS = internal standard ratio (peak response of oxycodone/peak response of ethylparaben) from the Read More
PENTAZOCINE INJECTION Chemical Information USP36–NF31 4734 1-Jun-2013 USP37–NF32 USP37–NF32 Line 1: Remove all chemical information.
POTASSIUM BICARBONATE EFFERVESCENT TABLETS FOR ORAL SOLUTION Assay USP36–NF31 4833 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Potassium stock solution and Standard preparations
to:
Standard stock solution and Standard solutions
AND
Line 1 of Procedure: Change
for Procedure in the Assay under Potassium Chloride Oral Solution.
to… Read More
POTASSIUM BICARBONATE AND POTASSIUM CHLORIDE FOR EFFERVESCENT ORAL SOLUTION Assay for potassium USP36–NF31 4834 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Potassium stock solution and Standard preparations
to:
Standard stock solution and Standard solutions
AND
Line 1 of Procedure: Change
for Procedure in the Assay under Potassium Chloride Oral Solution.
to… Read More
POTASSIUM BICARBONATE AND POTASSIUM CHLORIDE EFFERVESCENT TABLETS FOR ORAL SOLUTION Assay for potassium USP36–NF31 4834 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Potassium stock solution and Standard preparations
to:
Standard stock solution and Standard solutions
AND
Line 1 of Procedure: Change
for Procedure in the Assay under Potassium Chloride Oral Solution.
to… Read More